Who is sponsoring NCT05129072?

NCT05129072 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT05129072?

Interventions in NCT05129072: kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D.

What condition does NCT05129072 study?

NCT05129072 studies Contact Lens Wearer.

Is NCT05129072 still recruiting?

NCT05129072 is currently completed. Last updated 24 June 2025.

Are results published for NCT05129072?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-06-24 · How we verify

NCT05129072

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric Lenses

Completed NA Results posted Last updated 24 June 2025

What this trial tests

NA trial testing kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D in Contact Lens Wearer in 75 participants. Completed in 24 September 2021.

Timeline

25 August 2021

Primary endpoint
24 September 2021

24 September 2021

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	25 August 2021
Primary completion	24 September 2021
Estimated completion	24 September 2021
Sites	1 location across United States

Drugs / interventions tested

kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D

Conditions studied

Contact Lens Wearer — all drugs for Contact Lens Wearer →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

18 and older, any sex, with Contact Lens Wearer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Spherical Aberration Measurement Primary · 60 minutes

Spherical aberration (SA) occurs when light rays entering at different points of a spherical lens are not focused to the same point of the optical axis.

T01 (kali +6D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.162	± 0.187

T02 (kali +3D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.090	± 0.120

T03 (kali 0D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.017	± 0.133

T04 (kali -3D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.052	± 0.145

T05 (kali -6D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.062	± 0.158

T06 (kali -9D)

Group	Value	95% CI
Spherical Aberration of Kalifilcon A Daily Disposable Toric LD213001 Lens	0.102	± 0.164

Visibility of Toric Etch Mark by the Investigator Secondary · 60 minutes

Number of lenses the investigator could identify the toric etch mark

T01 kali +6D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	26

T02 kali +3D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	30

T03 kali +0D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	30

T04 kali -3D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	30

T05 kali -6D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	30

T06 kali -9D

Group	Value	95% CI
Kalifilcon A Daily Disposable Toric Etch Mark Visibility	30

Sponsor's own description

This objective of this clinical study aims to confirm whether multiple kalifilcon A daily disposable toric contact lenses are providing the intended level of spherical aberration correction when worn.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05129072 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 24 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05129072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing